(Q38079618)

28 August 2017

title

Ischemic stroke biomarkers in blood (English)

1 reference

28 August 2017

0 references

Lena Rothstein

1

1 reference

28 August 2017

Glen C Jickling

series ordinal

2

1 reference

28 August 2017

publication date

1 February 2013

1 reference

28 August 2017

published in

Biomarkers in Medicine

1 reference

28 August 2017

volume

7

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

37-47

1 reference

Invited article: searching for oracles? Blood biomarkers in acute stroke.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Potential biomarkers for the diagnosis of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Blood markers for the prognosis of ischemic stroke: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Multiple panel of biomarkers for TIA/stroke evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Novel diagnostic test for acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Early Biomarkers of Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Gene expression profiling of blood for the prediction of ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

The proteome of human brain after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

D-dimers predict stroke subtype when assessed early

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Signatures of cardioembolic and large-vessel ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Profiles of lacunar and nonlacunar stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Distinctive RNA expression profiles in blood associated with white matter hyperintensities in brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Extension of the thrombolytic time window with minocycline in experimental stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Unriddling the role of matrix metalloproteinases in human cerebral stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Matrix metalloproteinases in cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Inflammatory biomarkers in blood of patients with acute brain ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

The prediction of malignant cerebral infarction by molecular brain barrier disruption markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Duration of glutamate release after acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Lipoprotein-associated phospholipase A2 and risk of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Molecular biomarkers in stroke diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Anti-platelet therapy and aspirin resistance - clinically and chemically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Targeting the urine and plasma determinants of thromboxane A2 metabolism in detection of aspirin effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Raised plasma oxidised LDL in acute cerebral infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Ischemic transient neurological events identified by immune response to cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Transient ischemic attacks characterized by RNA profiles in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

Brain Extracellular Fluid Protein Changes in Acute Stroke Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.12.104

21 January 2018

Identifiers

DOI

10.2217/BMM.12.104

1 reference

28 August 2017

1 reference